# IFM 2018-01 (NCT03669445)

> Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03669445
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: University Hospital, Toulouse
- Conditions: Multiple Myeloma
- Interventions: Ixazomib; Lenalidomide; Dexamethasone; Daratumumab
- Enrollment: 45
- Primary outcome: minimal residual disease-negativity rate

## Indexed commentary on IFM 2018-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=ifm-2018-01-nct03669445